Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders

References

• Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. NY Acad. Sci.1003, 138–158 (2003).
   PubMed Web of Science ®Google Scholar
• Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS. Spectr.10, 808–819 (2005).
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ. The immune–glutamatergic interaction: towards an integrated view of schizophrenia. J. Psychiatr. Res. (2006) (In press).
   Google Scholar
• Müller N, Schwarz MJ. Inflammation induces serotonergic deficiency and glutamatergic hyperfunction in depression: towards an integrated view. Mol. Psychiatry (2006) (In press).
   Google Scholar
• Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology1, 179–186 (1988).
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol.41, 237–260 (2001).
   PubMed Web of Science ®Google Scholar
• Miller DW, Abercrombie ED. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull.40, 57–62 (1996).
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl Acad. Sci. USA93, 9235–9240 (1996).
   PubMed Web of Science ®Google Scholar
• Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett.20, 379–382 (1980).
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry51, 199–214 (1994).
   PubMed Web of Science ®Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry52, 998–1007 (1995).
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol.7, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int. J. Neuropsychopharmacol.8, 451–455 (2005).
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Cascella N, Fakouhl TD, Hertin RL. Enhancement of NMDA-mediated transmission in schizophrenia: effects of milacemide. In: Novel Antipsychotic Drugs. Meltzer HY (Ed.), Raven Press, NY, USA, 171–177 (1992).
   Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry56, 29–36 (1999).
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, Bressan RA, Stone JM et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry11, 118–119 (2006).
   PubMed Web of Science ®Google Scholar
• Matussek N. Neurobiologie und depression. Med. Monatsschr.3, 109–112 (1966).
   Google Scholar
• Coppen A, Swade C. 5-HT and depression: the present position. In: New Concepts In Depression. Briley M, Fillion G (Eds), MacMillan Press, London, UK, 120–136 (1988).
   Google Scholar
• Yan QS, Reith ME, Jobe PC, Dailey JW. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res.765, 149–158 (1997).
   PubMed Web of Science ®Google Scholar
• Martin P, Carlsson ML, Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport9, 2985–2988 (1998).
   PubMed Web of Science ®Google Scholar
• Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr.232, 299–304 (1982).
   PubMedGoogle Scholar
• Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry150, 1731–1733 (1993).
   PubMed Web of Science ®Google Scholar
• Mauri MC, Ferrara A, Boscati L et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology37, 124–129 (1998).
   PubMed Web of Science ®Google Scholar
• Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand.97, 302–308 (1998).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Gueorguieva R, Epperson CN et al. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry61, 705–713 (2004).
   PubMed Web of Science ®Google Scholar
• Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res.675, 157–164 (1995).
   PubMed Web of Science ®Google Scholar
• Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett.372, 173–177 (2004).
   PubMed Web of Science ®Google Scholar
• Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar. Disord.5, 257–264 (2003).
   PubMed Web of Science ®Google Scholar
• Maj J, Rogoz Z, Skuza G, Sowinska H. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharmacol.2, 37–41 (1992).
   PubMedGoogle Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol.185, 1–10 (1990).
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav.71, 341–344 (2002).
   PubMed Web of Science ®Google Scholar
• Ossowska G, Klenk-Majewska B, Szymczyk G. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J. Physiol. Pharmacol.48, 127–135 (1997).
   PubMed Web of Science ®Google Scholar
• Crane GE. Cyloserine as an antidepressant agent. Am. J. Psychiatry115, 1025–1026 (1959).
   PubMed Web of Science ®Google Scholar
• Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry32, 47–55 (1999).
   PubMed Web of Science ®Google Scholar
• Stryjer R, Strous RD, Shaked G et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol.18, 93–96 (2003).
   PubMed Web of Science ®Google Scholar
• Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients.Anesth. Analg.95, 114–118 (2002).
   PubMed Web of Science ®Google Scholar
• Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am. J. Psychiatry162, 1385–1386 (2005).
   PubMed Web of Science ®Google Scholar
• Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol. Neurobiol.24, 123–128 (2004).
   PubMed Web of Science ®Google Scholar
• Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive–compulsive disorder and major depressive disorder. Psychopharmacology (Berl.)167, 219–220 (2003).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am. J. Psychiatry161, 2132 (2004).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry161, 171–174 (2004).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry57, 430–432 (2005).
   PubMed Web of Science ®Google Scholar
• Brown AS, Begg MD, Gravenstein S et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry61, 774–780 (2004).
   PubMed Web of Science ®Google Scholar
• Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry58, 1032–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Westergaard T, Mortensen PB, Pedersen CB, Wohlfahrt J, Melbye M. Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence. Arch. Gen. Psychiatry56, 993–998 (1999).
   PubMed Web of Science ®Google Scholar
• Zuckerman L, Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J. Psychiatr. Res.39, 311–323 (2005).
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Abrahao AL, Foccacia R. Childhood meningitis, brain maturation and the risk of psychosis. Eur. Arch. Psychiatry Clin. Neurosci.254, 23–26 (2004).
   PubMed Web of Science ®Google Scholar
• Koponen H, Rantakallio P, Veijola J, Jones P, Jokelainen J, Isohanni M. Childhood central nervous system infections and risk for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.254, 9–13 (2004).
   PubMed Web of Science ®Google Scholar
• Körschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Müller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res.19, 103–109 (1996).
   PubMed Web of Science ®Google Scholar
• Bechter K, Schreiner V, Herzog S et al. CSF filtration as experimental therapy in therapyresistant psychoses in borna disease virus-seropositive patients. Psychiatr. Prax.30, 216–220 (2003).
   PubMed Web of Science ®Google Scholar
• Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun.15, 7–24 (2001).
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Yirmiya R, Schuld A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry58, 445–452 (2001).
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-α and IL-6 secretion. Psychoneuroendocrinology27, 945–956 (2002).
   PubMed Web of Science ®Google Scholar
• Zalcman S, Green-Johnson JM, Murray L et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res.643, 40–49 (1994).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun.15, 340–370 (2001).
   PubMed Web of Science ®Google Scholar
• Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry.10, 538–544 (2005).
   PubMed Web of Science ®Google Scholar
• Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur. Psychiatry20(Suppl. 3), S302–S306 (2005).
   PubMed Web of Science ®Google Scholar
• Rajkowska G. Astroglia in the cortex of schizophrenics: histopathology finding. World J. Biol. Psychiatry6, 74 (2005).
   Google Scholar
• Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol.164, 6166–6173 (2000).
   PubMed Web of Science ®Google Scholar
• Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci.246, 279–284 (1996).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Ackenheil M, Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J. Biol. Psychiatry1, 173–179 (2000).
   PubMedGoogle Scholar
• Sperner-Unterweger B, Miller C, Holzner B, Widner B, Fleischhacker WW, Fuchs D. Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Psychiatry, Psychoimmunology, and Viruses. Müller N (Ed.), Springer, Wien, Austria, 115–119 (1999).
   Google Scholar
• Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R. Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res.37, 147–160 (1991).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Riedel M, Ackenheil M, Müller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry47, 29–33 (2000).
   PubMed Web of Science ®Google Scholar
• Haack M, Hinze-Selch D, Fenzel T et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res.33, 407–418 (1999).
   PubMed Web of Science ®Google Scholar
• Molholm HB. Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr. Quarterly16, 565–571 (1942).
   Google Scholar
• Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J. Psychiatr. Res. (2006).
   PubMedGoogle Scholar
• Cazzullo CL, Scarone S, Grassi B et al. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry22, 947–957 (1998).
   PubMed Web of Science ®Google Scholar
• van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and behavioral measures in schizophrenia. In: Current Update in Psychoimmunology. Wieselmann G (Ed.), Springer, Wien, Austria, 51–55 (1997).
   Google Scholar
• Mittleman BB, Castellanos FX, Jacobsens LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol.159, 2994–2999 (1997).
   PubMed Web of Science ®Google Scholar
• Leonard BE. Is there an immunological basis for schizophrenia? Expert Rev. Clin. Immunol.1(1), 103–112 (2005).
   PubMedGoogle Scholar
• Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry17, 713–730 (1993).
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord.34, 301–309 (1995).
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Buckley P, Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci.244, 325–329 (1995).
   PubMed Web of Science ®Google Scholar
• Irwin M. Immune correlates of depression. Adv. Exp. Med. Biol.46, 1–24 (1999).
   Google Scholar
• Nunes SOV, Reiche EMV, Morimoto HK et al. Immune and hormonal activity in adults suffering from depression. Braz. J. Med. Biol. Res.35, 581–587 (2002).
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ. Immunology in anxiety and depression. In: Handbook of Depression and Anxiety. Kasper S, den Boer JA, Sitsen JMA (Eds), Marcel Dekker, NY, USA, 267–288 (2002).
   Google Scholar
• Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor α concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol.11, 203–208 (2001).
   PubMed Web of Science ®Google Scholar
• Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol. Bull.113, 472–486 (1993).
   PubMed Web of Science ®Google Scholar
• Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr. Scand.94, 198–204 (1996).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H. Different immune patterns in melancholic and non-melancholic major depression. Eur. Arch. Psychiatry Clin. Neurosci.251, 90–97 (2001).
   PubMed Web of Science ®Google Scholar
• Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC. Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res.11, 83–89 (1984).
   PubMed Web of Science ®Google Scholar
• Dunbar PR, Hill J, Neale TJ, Mellsop GW. Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol. Med.22, 1051–1057 (1992).
   PubMed Web of Science ®Google Scholar
• Maes M, Scharpe S, Meltzer HY et al. Increased neopterin and interferon-γ secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res.54, 143–160 (1994).
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Lin AH, Verkerk R et al. Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. J. Affect. Disord.48, 75–82 (1998).
   PubMed Web of Science ®Google Scholar
• Maes M, Scharpe S, Meltzer HY et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic–pituitary–adrenal axis in severe depression. Psychiatry Res.49, 11–27 (1993).
   PubMed Web of Science ®Google Scholar
• Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry29, 201–217 (2005).
   PubMed Web of Science ®Google Scholar
• Jun TY, Pae CU, Hoon H et al. Possible association between -G308A tumour necrosis factor-α gene polymorphism and major depressive disorder in the Korean population. Psychiatr. Genet.13, 179–181 (2003).
   PubMed Web of Science ®Google Scholar
• Fertuzinhos SM, Oliveira JR, Nishimura AL et al. Analysis of IL-1α, IL-1β, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia. J. Mol. Neurosci.22, 251–256 (2004).
   PubMed Web of Science ®Google Scholar
• Rosa A, Peralta V, Papiol S et al. Interleukin-1β (IL-1β) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am. J. Med. Genet. B NeuroPsychiatr. Genet.124, 10–14 (2004).
   Google Scholar
• Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin. Immunol. Immunopathol.78, 83–85 (1996).
   PubMedGoogle Scholar
• Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord.88, 167–173 (2005).
   PubMed Web of Science ®Google Scholar
• Sluzewska A, Rybakowski J, Bosmans E et al. Indicators of immune activation in major depression. Psychiatry Res.64, 161–167 (1996).
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res.29, 141–152 (1995).
   PubMed Web of Science ®Google Scholar
• Schäfer M, Horn M, Schmidt F et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α. Brain Behav. Immun.18, 555–562 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Ferrier IN, Kalaria RN et al. Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am. J. Psychiatry157, 1682–1684 (2000).
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Nunke K, Burchhardt M et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood–cerebrospinal fluid barrier. J. Neuroimmunol.47, 133–140 (1993).
   PubMed Web of Science ®Google Scholar
• Lane JH, Sasseville VG, Smith MO et al. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J. Neurovirol.2, 423–432 (1996).
   PubMed Web of Science ®Google Scholar
• Mendlovic S, Mozes E, Eilat E et al. Immune activation in non-treated suicidal major depression. Immunol. Lett.67, 105–108 (1999).
   PubMed Web of Science ®Google Scholar
• Penttinen J. Hypothesis: low serum cholesterol, suicide, and interleukin-2. Am. J. Epidemiol.141, 716–718 (1995).
   PubMed Web of Science ®Google Scholar
• Nassberger L, Traskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr. Scand.88, 48–52 (1993).
   PubMed Web of Science ®Google Scholar
• Baron DA, Hardie T, Baron SH. Possible association of interleukin-2 treatment with depression and suicide. J. Am. Osteopath. Assoc.93, 799–800 (1993).
   PubMedGoogle Scholar
• Kronfol Z, House JD. Immune function in mania. Biol. Psychiatry24, 341–343 (1988).
   PubMed Web of Science ®Google Scholar
• Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J. Neuroimmunol.150, 116–122 (2004).
   PubMed Web of Science ®Google Scholar
• Su KP, Leu SJ, Yang YY, Shen WW, Chou YM, Tsai SY. Reduced production of interferon-γ but not interleukin-10 in bipolar mania and subsequent remission. J. Affect. Disord.71, 205–209 (2002).
   PubMed Web of Science ®Google Scholar
• Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord.82, 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry53, 157–165 (2003).
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Lee BH et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res.129, 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• O’brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord.90, 263–267 (2006).
   PubMed Web of Science ®Google Scholar
• Meijer A, Zakay-Rones Z, Morag A. Post-influenzal psychiatric disorder in adolescents. Acta Psychiatr. Scand.78, 176–181 (1988).
   PubMed Web of Science ®Google Scholar
• Müller N, Gizycki-Nienhaus B, Günther W, Meurer M. Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid. Biol. Psychiatry31, 1151–1156 (1992).
   PubMed Web of Science ®Google Scholar
• Hall S, Smith A. Investigation of the effects and aftereffects of naturally occurring upper respiratory tract illnesses on mood and performance. Physiol. Behav.59, 569–577 (1996).
   PubMed Web of Science ®Google Scholar
• Yirmiya R, Weidenfeld J, Pollak Y et al. Cytokines, “depression due to a general medical condition,” and antidepressant drugs. Adv. Exp. Med. Biol.461, 283–316 (1999).
   PubMed Web of Science ®Google Scholar
• Pollak Y, Ovadia H, Goshen I et al. Behavioral aspects of experimental autoimmune encephalomyelitis. J. Neuroimmunol.104, 31–36 (2000).
   PubMed Web of Science ®Google Scholar
• Sakic B, Denburg JA, Denburg SD, Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull.41, 305–311 (1996).
   PubMed Web of Science ®Google Scholar
• Yirmiya R. Depression in medical illness: the role of the immune system. West J. Med.173, 333–336 (2000).
   PubMedGoogle Scholar
• Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J. Clin. Psychopharmacol.22, 86–90 (2002).
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon α-2b therapy.J. Clin. Psychiatry64, 708–714 (2003).
   PubMed Web of Science ®Google Scholar
• Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C. Gen. Hosp. Psychiatry26, 237–240 (2004).
   PubMed Web of Science ®Google Scholar
• Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-α treatment. Biol. Psychiatry (2006) (In press).
   PubMedGoogle Scholar
• Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry7, 468–473 (2002).
   PubMed Web of Science ®Google Scholar
• Capuron L, Neurauter G, Musselman DL et al. Interferon-α-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry54, 906–914 (2003).
   PubMed Web of Science ®Google Scholar
• Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon β-1α therapy in patients with multiple sclerosis. Mult. Scler.11, 175–181 (2005).
   PubMed Web of Science ®Google Scholar
• Amirkhani A, Rajda C, Arvidsson B et al. Interferon-β affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol.12, 625–631 (2005).
   PubMed Web of Science ®Google Scholar
• Marzi M, Vigano A, Trabattoni D et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin. Exp. Immunol.106, 127–133 (1996).
   PubMed Web of Science ®Google Scholar
• Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and pre-eclampsia. Clin. Exp. Immunol.117, 550–555 (1999).
   PubMed Web of Science ®Google Scholar
• Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci.71, 1837–1848 (2002).
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis.64, 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Stein GS. The pattern of mental change and body weight change in the first post-partum week. J. Psychosom. Res.24, 165–171 (1980).
   PubMed Web of Science ®Google Scholar
• Josefsson A, Berg G, Nordin C, Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet. Gynecol. Scand.80, 251–255 (2001).
   PubMed Web of Science ®Google Scholar
• O’Hara MW, Swain AM. Rates and risk of post-partum depression – a meta-analysis. In. Rev. Psychiatry8, 37–54 (1996).
   Web of Science ®Google Scholar
• Kohl C, Walch T, Huber R et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J. Affect. Disord.86, 135–142 (2005).
   PubMed Web of Science ®Google Scholar
• Gard PR, Handley SL, Parsons AD, Waldron G. A multivariate investigation of postpartum mood disturbance. Br. J. Psychiatry148, 567–575 (1986).
   PubMed Web of Science ®Google Scholar
• Abou-Saleh MT, Ghubash R, Karim L, Krymski M, Anderson DN. The role of pterins and related factors in the biology of early postpartum depression. Eur. Neuropsychopharmacol.9, 295–300 (1999).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Schwarz MJ et al. Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: Current Update in Psychoimmunology. Wieselmann G (Ed.), Springer, Wien, Austria, 57–67 (1997).
   Google Scholar
• Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.247, 308–313 (1997).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R. Increase in expression of adhesion molecule receptors on T-helper cells during antipsychotic treatment and relationship to blood–brain barrier permeability in schizophrenia. Am. J. Psychiatry156, 634–636 (1999).
   PubMed Web of Science ®Google Scholar
• Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr. Neurol. Psychiatr.69(Suppl. 2), S65–S74 (2001).
   Google Scholar
• Ozek M, Toreci K, Akkok I, Guvener Z. Influence of therapy on antibody-formation. Psychopharmacologia.21, 401–412 (1971).
   PubMedGoogle Scholar
• Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res.96, 75–80 (2000).
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine9, 853–858 (1997).
   PubMed Web of Science ®Google Scholar
• Bengtsson BO, Zhu J, Thorell LH, Olsson T, Link H, Walinder J. Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats. J. Neuroimmunol.39, 109–122 (1992).
   PubMed Web of Science ®Google Scholar
• Song C, Leonard BE. An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med. Sci. Res.22, 313–314 (1994).
   Google Scholar
• Zhu J, Bengtsson BO, Mix E, Thorell LH, Olsson T, Link H. Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immunopharmacology27, 225–244 (1994).
   PubMedGoogle Scholar
• Maes M, Song C, Lin AH et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology20, 370–379 (1999).
   PubMed Web of Science ®Google Scholar
• Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol.41, 534–538 (1995).
   PubMed Web of Science ®Google Scholar
• Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology22, 370–379 (2000).
   PubMed Web of Science ®Google Scholar
• Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol.5, 401–412 (2002).
   PubMed Web of Science ®Google Scholar
• Basterzi AD, Aydemir C, Kisa C et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol.20, 473–476 (2005).
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci.247, 228–233 (1997).
   PubMed Web of Science ®Google Scholar
• Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-α in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) (In press).
   PubMedGoogle Scholar
• Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci.762, 474–476 (1995).
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci.247, 228–233 (1997).
   PubMed Web of Science ®Google Scholar
• Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behavior: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. Int. J. Neuropsychopharmacol.5, 389–399 (2002).
   PubMed Web of Science ®Google Scholar
• Mtabaji JP, Manku MS, Horrobin DF. Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2. Prostaglandins14, 125–132 (1977).
   PubMedGoogle Scholar
• Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum.42, 2561–2568 (1999).
   PubMedGoogle Scholar
• Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor α in patients with depression: normalization during electroconvulsive therapy. J. ECT19, 183–188 (2003).
   PubMed Web of Science ®Google Scholar
• Dimitrov S, Lange T, Tieken S, Fehm HL, Born J. Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans. Brain Behav. Immun.18, 341–348 (2004).
   PubMed Web of Science ®Google Scholar
• Benedetti F, Lucca A, Brambilla F, Colombo C, Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog. Neuropsychopharmacol. Biol. Psychiatry26, 1167–1170 (2002).
   PubMed Web of Science ®Google Scholar
• Blumenthal JA, Babyak MA, Moore KA et al. Effects of exercise training on older patients with major depression. Arch. Intern. Med.159, 2349–2356 (1999).
   PubMed Web of Science ®Google Scholar
• Martinsen EW. Benefits of exercise for the treatment of depression. Sports Med.9, 380–389 (1990).
   PubMed Web of Science ®Google Scholar
• Babyak M, Blumenthal JA, Herman S et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom. Med.62, 633–638 (2000).
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Febbraio M. Muscle-derived interleukin-6 – a possible link between skeletal muscle, adipose tissue, liver, and Brain. Brain Behav. Immun.19, 371–376 (2005).
   PubMed Web of Science ®Google Scholar
• Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol.54, 1–78 (1993).
   PubMed Web of Science ®Google Scholar
• Ostrowski K, Schjerling P, Pedersen BK. Physical activity and plasma interleukin-6 in humans--effect of intensity of exercise. Eur. J. Appl. Physiol.83, 512–515 (2000).
   PubMed Web of Science ®Google Scholar
• Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J. Physiol.515(Pt 1), 287–291 (1999).
   PubMed Web of Science ®Google Scholar
• Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J. Appl. Physiol.98, 1154–1162 (2005).
   PubMed Web of Science ®Google Scholar
• Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J.17, 884–886 (2003).
   PubMed Web of Science ®Google Scholar
• Keller C, Keller P, Giralt M, Hidalgo J, Pedersen BK. Exercise normalises overexpression of TNF-α in knockout mice. Biochem. Biophys. Res. Commun.321, 179–182 (2004).
   PubMed Web of Science ®Google Scholar
• Ito Y, Yonekura R, Maruta K et al. Tryptophan metabolism was accelerated by exercise in rat. Adv. Exp. Med. Biol.527, 531–535 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Ding YH, Rafols JA, Lai Q, McAllister JP, Ding Y. Increased astrocyte proliferation in rats after running exercise. Neurosci. Lett.386, 160–164 (2005).
   PubMed Web of Science ®Google Scholar
• Nybo L, Nielsen B, Pedersen BK, Moller K, Secher NH. Interleukin-6 release from the human brain during prolonged exercise. J. Physiol.542, 991–995 (2002).
   PubMed Web of Science ®Google Scholar
• Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol.100, 124–139 (1999).
   PubMed Web of Science ®Google Scholar
• Dietrich MO, Tort AB, Schaf DV et al. Increase in serum S100B protein level after a swimming race. Can. J. Appl. Physiol.28, 710–716 (2003).
   PubMedGoogle Scholar
• Otto M, Holthusen S, Bahn E et al. Boxing and running lead to a rise in serum levels of S-100B protein. Int. J. Sports Med.21, 551–555 (2000).
   PubMed Web of Science ®Google Scholar
• Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev.45, 309–379 (1993).
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther.303, 1–10 (2002).
   PubMed Web of Science ®Google Scholar
• Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem.52, 1319–1328 (1989).
   PubMed Web of Science ®Google Scholar
• Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci.21, 7463–7473 (2001).
   PubMed Web of Science ®Google Scholar
• Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol.24, 242–248 (2003).
   PubMed Web of Science ®Google Scholar
• Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem.261, 3648–3653 (1986).
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis.15, 618–629 (2004).
   PubMed Web of Science ®Google Scholar
• Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol. Today21, 141–147 (2000).
   PubMedGoogle Scholar
• Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol.527, 105–112 (2003).
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J. Neuroinflammation2, 16 (2005).
   PubMedGoogle Scholar
• Alberati GD, Ricciardi CP, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-γ in murine cloned macrophages and microglial cells. J. Neurochem.66, 996–1004 (1996).
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today20, 469–473 (1999).
   PubMedGoogle Scholar
• Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med.189, 1363–1372 (1999).
   PubMed Web of Science ®Google Scholar
• Weiss G, Murr C, Zoller H et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin. Exp. Immunol.116, 435–440 (1999).
   PubMed Web of Science ®Google Scholar
• Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood106, 2375–2381 (2005).
   PubMed Web of Science ®Google Scholar
• Kwidzinski E, Bunse J, Aktas O et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J.19, 1347–1349 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson CM, Hale PT, Carlin JM. The role of IFN-γ and TNF-α-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J. Interferon Cytokine Res.25, 20–30 (2005).
   PubMed Web of Science ®Google Scholar
• Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN. CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry40, 405–406 (1983).
   PubMed Web of Science ®Google Scholar
• Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia45, 535–541 (1989).
   PubMedGoogle Scholar
• Taylor MW, Feng GS. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J.5, 2516–2522 (1991).
   PubMed Web of Science ®Google Scholar
• Lidberg L, Belfrage H, Bertilsson L, Evenden MM, Asberg M. Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders. Acta Psychiatr. Scand.101, 395–402 (2000).
   PubMed Web of Science ®Google Scholar
• Mann JJ, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol. Psychiatry41, 162–171 (1997).
   PubMed Web of Science ®Google Scholar
• Nordstrom P, Samuelsson M, Asberg M et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat. Behav.24, 1–9 (1994).
   PubMed Web of Science ®Google Scholar
• Xiao BG, Link H. Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? Immunol. Today20, 477–479 (1999).
   PubMedGoogle Scholar
• Aloisi F, Penna G, Cerase J, Menendez IB, Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol.159, 1604–1612 (1997).
   PubMed Web of Science ®Google Scholar
• Lara DR, Gama CS, Belmonte-de-Abreu P et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J. Psychiatr. Res.35, 11–14 (2001).
   PubMed Web of Science ®Google Scholar
• Schroeter ML, Abdul-Khaliq H, Fruhauf S et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res.62, 231–236 (2003).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Ponath G, Arolt V. S100B in schizophrenic psychosis. Int. Rev. Neurobiol.59, 445–470 (2004).
   PubMed Web of Science ®Google Scholar
• Schmitt A, Bertsch T, Henning U et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr. Res.80, 305–313 (2005).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Falkai P, Ponath G et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry9, 897–899 (2004).
   PubMed Web of Science ®Google Scholar
• Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett.271, 126–128 (1999).
   PubMed Web of Science ®Google Scholar
• Cotter D, Pariante C, Rajkowska G. Glial pathology in major psychiatric disorders. In: The Post-Mortem Brain In Psychiatric Research. Agam G, Belmaker RH, Everall I (Eds), Kluwer Acad Pub, Boston, MA, USA, 291–324 (2002).
   Google Scholar
• Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA95, 13290–13295 (1998).
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Miguel-Hidalgo JJ, Wei J et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry45, 1085–1098 (1999).
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry49, 741–752 (2001).
   PubMed Web of Science ®Google Scholar
• Rajkowska G. Depression: what we can learn from postmortem studies. Neuroscientist9, 273–284 (2003).
   PubMed Web of Science ®Google Scholar
• Johnston-WilsonNL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol. Psychiatry5, 142–149 (2000).
   PubMed Web of Science ®Google Scholar
• Miguel-Hidalgo JJ, Baucom C, Dilley G et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol. Psychiatry48, 861–873 (2000).
   PubMed Web of Science ®Google Scholar
• Si X, Miguel-Hidalgo JJ, O’Dwyer G, Stockmeier CA, Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology29, 2088–2096 (2004).
   PubMed Web of Science ®Google Scholar
• Davis S, Thomas A, Perry R, Oakley A, Kalaria RN, O’Brien JT. Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. J. Neurol. Neurosurg. Psychiatry73, 556–560 (2002).
   PubMed Web of Science ®Google Scholar
• Choudary PV, Molnar M, Evans SJ et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA102, 15653–15658 (2005).
   PubMed Web of Science ®Google Scholar
• Gegelashvili G, Robinson MB, Trotti D, Rauen T. Regulation of glutamate transporters in health and disease. Prog. Brain Res.132, 267–286 (2001).
   PubMedGoogle Scholar
• Auger C, Attwell D. Fast removal of synaptic glutamate by postsynaptic transporters. Neuron28, 547–558 (2000).
   PubMed Web of Science ®Google Scholar
• Danbolt NC. Glutamate uptake. Prog. Neurobiol.65, 1–105 (2001).
   PubMed Web of Science ®Google Scholar
• Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J.326, 351–356 (1997).
   PubMed Web of Science ®Google Scholar
• Speciale C, Schwarcz R. On the production and disposition of quinolinic acid in rat brain and liver slices. J. Neurochem.60, 212–218 (1993).
   PubMed Web of Science ®Google Scholar
• Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R. Kynurenate production by cultured human astrocytes. J. Neural Transm.110, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ. Aβ 1–42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport14, 2311–2315 (2003).
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Carpenedo R, Moroni F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J. Neurochem.67, 692–698 (1996).
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res.1073–1074, 25–37 (2006).
   PubMed Web of Science ®Google Scholar
• Saito K, Crowley JS, Markey SP, Heyes MP. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J. Biol. Chem.268, 15496–15503 (1993).
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J.12, 881–896 (1998).
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Crowley JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain115, 1249–1273 (1992).
   PubMed Web of Science ®Google Scholar
• Martin A, Heyes MP, Salazar AM et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J. Neuropsychiatry Clin. Neurosci.4, 270–279 (1992).
   PubMed Web of Science ®Google Scholar
• Martin A, Heyes MP, Salazar AM, Law WA, Williams J. Impaired motor skill learning, slowed reaction time, and elevated cerebrospinal fluid quinilonic acid in a sub-group of HIV-infected individuals. Neuropsychology7, 147–149 (1993).
   Google Scholar
• Heyes MP, Brew BJ, Martin A et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol.29, 202–209 (1991).
   PubMed Web of Science ®Google Scholar
• Lapin IP. Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv. Exp. Med. Biol.527, 121–125 (2003).
   PubMed Web of Science ®Google Scholar
• Fedele E, Foster AC. An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience52, 911–917 (1993).
   PubMed Web of Science ®Google Scholar
• Chen Q, Surmeier DJ, Reiner A. NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp. Neurol.159, 283–296 (1999).
   PubMed Web of Science ®Google Scholar
• Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses61, 519–525 (2003).
   PubMed Web of Science ®Google Scholar
• Myint AM, Verkerk R, Kim YK, Scharpe S, Steinbusch HW, Leonard BE. Tryptophan depletion and kynurenine pathway in depression: evidence of imbalance neuroprotection-neurodegeneration. Neuropsychopharmacol.15(Suppl. 3), 399 (2005).
   Web of Science ®Google Scholar
• Alberati GD, Cesura AM. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino. Acids14, 251–255 (1998).
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol.120, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Kaiya H, Uematsu M, Ofuji M et al. Elevated plasma prostaglandin E2 levels in schizophrenia. J. Neural Transm.77, 39–46 (1989).
   PubMed Web of Science ®Google Scholar
• Das I, Khan NS. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot. Essent. Fatty Acids58, 165–168 (1998).
   PubMed Web of Science ®Google Scholar
• Yokota O, Terada S, Ishihara T et al. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry28, 715–721 (2004).
   PubMed Web of Science ®Google Scholar
• Dai YQ, Jin DZ, Zhu XZ, Lei DL. Triptolide inhibits COX-2 expression via NF-κ B pathway in astrocytes. Neurosci. Res.55, 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Durrenberger P et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol.6, 12 (2006).
   PubMed Web of Science ®Google Scholar
• Hinz B, Brune K, Pahl A. Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem. Biophys. Res. Commun.272, 744–748 (2000).
   PubMed Web of Science ®Google Scholar
• Song C, Lin A, Bonaccorso S et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord.49, 211–219 (1998).
   PubMed Web of Science ®Google Scholar
• Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry23, 326–334 (1988).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Skwerer RG, Barna B et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res.17, 41–47 (1986).
   PubMed Web of Science ®Google Scholar
• Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev.15, 185–215 (1991).
   PubMed Web of Science ®Google Scholar
• Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am. J. Psychiatry144, 641–645 (1987).
   PubMed Web of Science ®Google Scholar
• Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology29, 1765–1781 (2004).
   PubMed Web of Science ®Google Scholar
• Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology30, 846–856 (2005).
   PubMed Web of Science ®Google Scholar
• Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A. Acute phase proteins in major depression. J. Psychosom. Res.43, 529–534 (1997).
   PubMed Web of Science ®Google Scholar
• Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res.12, 29–34 (1994).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr. Scand.97, 309–313 (1998).
   PubMed Web of Science ®Google Scholar
• Ershler WB, Sun WH, Binkley N et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res.12, 225–230 (1993).
   PubMedGoogle Scholar
• O’brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum. Psychopharmacol.19, 397–403 (2004).
   PubMed Web of Science ®Google Scholar
• Pugh CR, Nguyen KT, Gonyea JL et al. Role of interleukin-1 β in impairment of contextual fear conditioning caused by social isolation. Behav. Brain Res.106, 109–118 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Deak T, Owens SM et al. Exposure to acute stress induces brain interleukin-1β protein in the rat. J. Neurosci.18, 2239–2246 (1998).
   PubMed Web of Science ®Google Scholar
• Bacher M, Meinhardt A, Lan HY et al. MIF expression in the rat brain: implications for neuronal function. Mol. Med.4, 217–230 (1998).
   PubMed Web of Science ®Google Scholar
• Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J. Neurol. Sci.179, 127–131 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ogata A, Tashiro K et al. Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim. Biophys. Acta1517, 100–106 (2000).
   PubMed Web of Science ®Google Scholar
• Madrigal JL, Garcia-Bueno B, Moro MA, Lizasoain I, Lorenzo P, Leza JC. Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur. J. Neurosci.18, 1701–1705 (2003).
   PubMed Web of Science ®Google Scholar
• Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science233, 652–654 (1986).
   PubMed Web of Science ®Google Scholar
• Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science238, 524–526 (1987).
   PubMed Web of Science ®Google Scholar
• Sundar SK, Cierpial MA, Kilts C, Ritchie JC, Weiss JM. Brain IL-1-induced immunosuppression occurs through activation of both pituitary-adrenal axis and sympathetic nervous system by corticotropin-releasing factor. J. Neurosci.10, 3701–3706 (1990).
   PubMed Web of Science ®Google Scholar
• Weiss JM, Quan N, Sundar SK. Immunological consequences of Interleukin-1 in the brain. Neuropsychopharmacol.10, 833 (1994).
   Google Scholar
• Sapolsky RM. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J. Neurosci.5, 1228–1232 (1985).
   PubMed Web of Science ®Google Scholar
• Woolley CS, Gould E, McEwen BS. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res.531, 225–231 (1990).
   PubMed Web of Science ®Google Scholar
• Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J. Psychiatry Neurosci.29, 417–426 (2004).
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res.655, 251–254 (1994).
   PubMed Web of Science ®Google Scholar
• Stein-Behrens BA, Lin WJ, Sapolsky RM. Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus. J. Neurochem.63, 596–602 (1994).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kimoto T, Tanabe N, Hattori TA, Yasumatsu N, Kawato S. Corticosterone acutely prolonged N-methyl-D-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons. J. Neurochem.83, 1441–1451 (2002).
   PubMed Web of Science ®Google Scholar
• Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol.171, 72–85 (2006).
   PubMed Web of Science ®Google Scholar
• Cao C, Matsumura K, Ozaki M, Watanabe Y. Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J. Neurosci.19, 716–725 (1999).
   PubMed Web of Science ®Google Scholar
• Quinlivan JA, Beazley LD, Archer M, Evans SF, Newnham JP, Dunlop SA. Repeated prenatal corticosteroids reduce glial fibrillary acidic protein in the ovine central nervous system. J. Perinat. Med.30, 209–219 (2002).
   PubMed Web of Science ®Google Scholar
• Nichols NR, Zieba M, Bye N. Do glucocorticoids contribute to brain aging? Brain Res. Brain Res. Rev.37, 273–286 (2001).
   PubMedGoogle Scholar
• Pyeon D, Diaz FJ, Splitter GA. Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J. Virol.74, 5740–5745 (2000).
   PubMed Web of Science ®Google Scholar
• Stolina M, Sharma S, Lin Y et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol.164, 361–370 (2000).
   PubMed Web of Science ®Google Scholar
• Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol.23, 144–150 (2002).
   PubMed Web of Science ®Google Scholar
• Litherland SA, Xie XT, Hutson AD et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J. Clin. Invest.104, 515–523 (1999).
   PubMed Web of Science ®Google Scholar
• Schwieler L, Erhardt S, Erhardt C, Engberg G. Prostaglandin-mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J. Neural Transm.112, 863–872 (2005).
   PubMed Web of Science ®Google Scholar
• Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int. J. Psychiatry Med.26, 25–34 (1996).
   PubMed Web of Science ®Google Scholar
• Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin. Rheumatol.18, 339–345 (1999).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry159, 1029–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Dehning S et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology29, 176 (2004).
   Web of Science ®Google Scholar
• Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.255, 149–151 (2005).
   PubMed Web of Science ®Google Scholar
• Müller N, Ulmschneider M, Scheppach C et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci.254, 14–22 (2004).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry57, 1594–1596 (2005).
   PubMed Web of Science ®Google Scholar
• Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J. Neurosci. Res.68, 337–343 (2002).
   PubMed Web of Science ®Google Scholar
• Hu F, Wang X, Pace TW, Wu H, Miller AH. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol. Psychiatry10, 426–428 (2005).
   PubMed Web of Science ®Google Scholar
• Song C, Leonard BE. Fundamentals of psychoneuroimmunology. J Wiley and Sons, Chichester, NY, USA (2000).
   Google Scholar
• Sandrini M, Vitale G, Pini LA. Effect of rofecoxib on nociception and the serotonin system in the rat Brain.Inflamm. Res.51, 154–159 (2002).
   PubMed Web of Science ®Google Scholar
• Salzberg-Brenhouse HC, Chen EY, Emerich DF et al. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J. Pharmacol. Exp. Ther.306, 218–228 (2003).
   PubMed Web of Science ®Google Scholar
• Collantes-Esteves E, Fernandez-Perrez CH. Improved self-control of ostheoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in spain. Curr. Med. Res. Opin.19, 402–410 (2003).
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ, Dehning S et al. The cyclo-oxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry (2006) (In press).
   Google Scholar
• Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side effects: from light to shadow. Curr. Pharm. Des.12, 971–975 (2006).
   PubMed Web of Science ®Google Scholar
• Brophy JM. Celecoxib and cardiovascular risks. Expert Opin. Drug Saf.4, 1005–1015 (2005).
   PubMedGoogle Scholar
• Wang D, Wang M, Cheng Y, FitzGerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol.5, 204–210 (2005).
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352, 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352, 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar